Generalized anxiety disorder is characterized by excessive, difficult-to-control worry across multiple domains accompanied by physical and cognitive symptoms that cause significant distress or impairment.
Helus Pharma announced publication in Nature Medicine of Phase 2a trial results showing its short-acting psychedelic SPL026 met its primary endpoint with significant reductions in depressive symptoms at two weeks in moderate-to-severe MDD patients. The company also appointed a new SVP of Medical Affairs and is advancing HLP003 (Breakthrough Therapy Designation from FDA) and HLP004 in its pipeline.
Compass Pathways reported positive late-stage COMP360 psilocybin data in treatment-resistant depression and plans FDA talks ahead of a filing between October and December. The update lifted shares across several psychedelics developers.
New clinical trials show single doses of psilocybin and LSD produce significant, lasting reductions in OCD and generalized anxiety disorder symptoms for up to 12 weeks, marking a potential shift from daily medication regimens.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07774481 |
Anxiety Skills Study |
RECRUITING | NA |
| NCT07770919 |
Continuous Theta Burst Stimulation for Generalized Anxiety Disorder |
NOT_YET_RECRUITING | NA |
| NCT07767903 |
A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder |
RECRUITING | PHASE3 |
| NCT07759128 |
A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder |
RECRUITING | PHASE3 |
| NCT07719816 |
Qualitative Study of Student Financial Insecurity and Psychiatry |
NOT_YET_RECRUITING | |
| NCT07686354 |
LIFU for Chronic Pain and Generalized Anxiety Disorder |
NOT_YET_RECRUITING | NA |
| NCT07618208 |
Student Precarity and Psychiatry |
NOT_YET_RECRUITING | |
| NCT07579897 |
Group vs. Individual Metacognitive Therapy for Generalized Anxiety Disorder |
RECRUITING | NA |
| NCT07577271 |
THE EFFECT OF YOGA-ASSISTED COGNITIVE BEHAVIORAL THERAPY ON INDIVIDUALS DIAGNOSED WITH GENERALIZED ANXIETY DISORDER |
NOT_YET_RECRUITING | NA |
| NCT07489651 |
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder |
RECRUITING | PHASE2 |
